Rishabh Jain: What ALTAIR Teaches Us About ctDNA-Positive CRC
oncodaily - Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: “ctDNA-positive CRC after curative surgery sounds like the perfect place to intervene. But ALTAIR says: not so fast. Phase 3, double-blind […]
AI Summary: Coverage examines ALTAIR, a randomized phase‑3 trial testing post‑adjuvant chemotherapy for patients with resected colorectal cancer who are ctDNA‑positive. Experts dissect trial design, endpoints and implications for ctDNA‑guided treatment decisions, debating whether circulating tumor DNA should steer adjuvant therapy or remain an elegant biomarker with stubborn practical hurdles.
Related Stories
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 8 hrs
AI model generalizes to predict immunotherapy response across cancers / 6 days
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 5 wks
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 5 wks
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try None, Infectious Disease, Novo Nordisk, Cancer Research and look for the RSS link.
StackHealth Time Machine